Recombinant Anti-Kit x Anti-VCAM-1 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-Kit antibody variable domain is fused to CH1 and the other scFv from an anti-VCAM-1 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can retarget hematopoietic stem cells toinjured myocardium. It is designed for the research of Cardiovascular disease therapy.